Spin-offs/Alkermes plc → Mural Oncology plc

Mural Oncology plcMURA

Spin-off from Alkermes plc (ALKS) · Nov 15, 2023 · Nasdaq

Announced

—

Form 10 filed

Oct 10, 2023

Record date

—

Distributed

Nov 15, 2023

Ratio

1 : 10

Debt loaded

—

Cash to parent

—

Latest filing

Oct 26, 2023

one ordinary share of Mural Oncology for every ten ordinary shares of Alkermes

Documents

Form 10 Information statement New company filings Parent filings

Both companies today

The new company

Mural Oncology plcMURA

Not in MoatScope's coverage yet — numbers appear once the shares trade and the first filings land.

The parent

Alkermes plcALKS

Market cap

$8.29B

Moat

Narrow

Quality

Price

$46.10

Fair value

$10.71

Price / FV

4.42×

Moat ratings, quality scores and fair value estimates are MoatScope research opinions and refresh with the data pipeline. Price / FV below 1.00× means the shares trade under our base-case estimate.

What is being separated

Mural Oncology holds Alkermes' clinical-stage oncology programs, separated from the neuroscience business as an independent, Nasdaq-listed biotechnology company.

Stated rationaleAlkermes said separating oncology from neuroscience would unlock value and give each business operational focus and strategic flexibility.

The four questions

The four-question write-up for Mural Oncology plc is pending. Terms, documents and both companies’ numbers above are live; the checklist is added once the information statement has been worked through.

Not investment advice. Terms are as stated in the latest filing; spin-off shares are often thinly covered and volatile in their first months.